Loading...

IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity

Activating mutations in KRAS are prevalent in cancer, but therapies targeted to oncogenic RAS have been ineffective to date. These results argue that targeting downstream effectors of RAS will be an alternative route for blocking RAS-driven oncogenic pathways. We and others have shown that oncogenic...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Bassères, Daniela S., Ebbs, Aaron, Cogswell, Patricia C., Baldwin, Albert S.
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2014
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063255/
https://ncbi.nlm.nih.gov/pubmed/24955217
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!